9th Circ. Won't Rethink FCA Disclosure Ruling Against Valeant
By Bonnie Eslinger · January 5, 2024, 8:24 PM EST
A Ninth Circuit panel on Friday denied drugmaker Valeant Pharmaceuticals' request to review its decision to revive a False Claims Act suit accusing Valeant of fraudulently obtaining a patent to extend...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login